Sight Sciences, Inc.
SGHT
Positions held
Your positionsSGHT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $466.60M | Enterprise value | $428.82M | Trailing P/E | — | Forward P/E | -19.60 |
| PEG | — | Price / book | 8.76 | Beta | 2.45 | Dividend yield | 0.00% |
| Revenue growth | 19.5% | Earnings growth | — | Gross margin | 88.0% | Operating margin | -16.6% |
| Profit margin | -35.7% | ROE | -48.4% | ROA | -10.8% | Debt / equity | 0.79 |
| Current ratio | 4.95 | Free cash flow | -$8.61M | Analyst recommendation | buy | Mean target | $9.40 |
| 52w high | $9.71 | 52w low | $3.19 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $23.4M | $19.7M | $20.4M | $19.9M | $19.6M | — |
| Op margin | -16.6% | -63.0% | -18.0% | -39.7% | -59.6% | — |
| Net income | -$4.4M | -$13.0M | -$4.2M | -$8.2M | -$11.9M | — |
| Gross margin | 91.4% | 86.2% | 87.3% | 86.4% | 84.8% | — |
| Gross profit | $21.4M | $17.0M | $17.8M | $17.2M | $16.6M | — |
| Operating income | -$3.9M | -$12.4M | -$3.7M | -$7.9M | -$11.7M | — |
- Revenue +19% vs prior quarter ($23M vs $20M).
- Gross margin 91.4% (was 86.2% prior quarter).
- Operating margin expanded to -16.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $77.4M | $79.9M | $81.1M | $71.3M | — |
| Op margin | -48.0% | -63.3% | -70.7% | -117.7% | — |
| Net income | -$38.4M | -$51.5M | -$55.5M | -$86.2M | — |
| Gross margin | 86.2% | 85.5% | 85.3% | 82.7% | — |
| Gross profit | $66.7M | $68.3M | $69.2M | $59.0M | — |
| Operating income | -$37.1M | -$50.5M | -$57.3M | -$84.0M | — |
Headlines — positive tone
• [OK · fundamentals] Sight Sciences Inc (SGHT) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and Raised ...
News
2026-10-08 · Sight Sciences (SGHT) Stock Gets Fair Value Boost After Analyst Target Increases
2026-09-01 · Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
2026-08-20 · GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
2026-08-19 · Sector Update: Healthcare Stocks Gain Wednesday Afternoon
2026-08-19 · Sector Update: Healthcare Stocks Higher in Wednesday Trading
2026-08-19 · Sight Sciences Gets US FDA Label Expansion for TearCare Dry Eye Treatment
2026-08-12 · Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript
2026-08-06 · UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating
2026-08-06 · Sight Sciences Inc (SGHT) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and Raised ...
2026-08-06 · Sight Sciences Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns